Chronic pelvic pain remains a significant clinical challenge, often refractory to conservative and interventional treatments. Superior hypogastric plexus block is an established technique; however, conventional anterior and posterior approaches may be limited by anatomical variability and potential risks to adjacent structures. Based on these anatomical findings, we propose that a posterior transosseous S1 pedicular approach represents a novel and anatomically robust corridor for accessing the superior hypogastric plexus. We hypothesize that the highly reproducible osseous anatomy of the S1 pedicle, combined with its consistent spatial relationship to the anterior sacral cortex and retroperitoneal compartment, may enable precise and fluoroscopically reproducible instrument guidance toward the plexus. Furthermore, this trajectory may mitigate the anatomical variability and procedural limitations associated with conventional anterior or paravertebral techniques while potentially reducing the risk of inadvertent injury to adjacent visceral, vascular, and neural structures. This concept is based on anatomical reasoning and fluoroscopic observations obtained during cadaveric anatomical orientation, suggesting that a transosseous trajectory through the S1 pedicle toward the anterior sacral cortex may offer improved spatial control and reproducibility compared with soft-tissue-based approaches. The proposed pathway remains conceptual and is not intended for clinical application at this stage. Further cadaveric, imaging-based, and clinical studies are required to evaluate its anatomical validity, safety, and potential clinical relevance.

Antimitochondrial antibody (AMA)-negative primary biliary cholangitis (PBC) is a rare presentation of PBC that comprises 5%–10% of all PBC patients. The pathogenesis of AMA-negative PBC appears to be similar to that of AMA-positive PBC. AMA-negative PBC presents similarly to AMA-positive PBC, with symptoms of cholestasis, fatigue, and pruritus most commonly reported. Defective bicarbonate production, resulting in acidification of bile and bile acids, has been proposed as the primary mechanism of damage to bile ducts and hepatocytes and is reflected in elevations of alkaline phosphatase and aminotransferases. Chronic damage can lead to the development of cirrhosis. The diagnosis is made by the finding of AMA negativity by ELISA or assays of similar sensitivity and a positive PBC-specific antinuclear antibody (ANA; anti-glycoprotein 210 and anti-speckled 100 kDa protein) test. In cases in which anti-glycoprotein 210 and anti-speckled 100 kDa protein assays are also negative, a liver biopsy is required to make the diagnosis after exclusion of other causes of cholestasis by magnetic resonance cholangiopancreatography or endoscopic retrograde cholangiopancreatography. Treatment for AMA-negative PBC is the same as for AMA-positive cases, with ursodeoxycholic acid as the first-line treatment. Current treatment is most effective in early stages, where it slows but does not eliminate progression. Risk stratification by validated tools such as the GLOBE and UK-PBC scores remains useful in AMA-negative PBC.

Primary biliary cholangitis (PBC) significantly impairs health-related quality of life (HRQL), yet the impact of disease stage and fatigue on HRQL and psychological status remains insufficiently quantified. This study aimed to investigate differences in HRQL across disease stages and the impact of fatigue in patients with PBC.

This cross-sectional study recruited 219 patients with PBC from two Chinese tertiary hospitals (2011–2024). After excluding one preclinical case, 218 patients were analyzed. Quality of life was assessed using the validated Chinese versions of the SF-36 and Chronic Liver Disease Questionnaire (CLDQ); psychological status was assessed using the Self-Rating Anxiety Scale and Self-Rating Depression Scale. Between-group differences were quantified by mean differences (MDs) and odds ratios (ORs) with 95% confidence intervals (CIs). Baseline characteristics were balanced across stages (all P > 0.05).

Of the 218 patients (90.4% female; mean age, 57.2 ± 10.3 years), 41 were in the clinical stage, 75 in the fibrosis stage, and 102 in the cirrhosis stage. SF-36 scores were lowest in the cirrhosis stage (e.g., Physical Functioning MD, 17.26; 95% CI, 6.93–27.59 vs. clinical stage), with similar declines in CLDQ domains. Anxiety was highest in the clinical stage (58.5%; OR vs. cirrhosis, 4.13; 95% CI, 1.92–8.92), whereas depression was highest in the cirrhosis stage (55.9%; OR vs. clinical stage, 4.50; 95% CI, 1.95–10.38). Fatigue prevalence was 66.1% and increased with disease stage. Patients with fatigue had lower SF-36 scores in Physical Functioning, Bodily Pain, Vitality, Mental Health, and Physical Component Summary (e.g., Physical Component Summary MD, 38.22; 95% CI, 10.41–66.02).

HRQL declines progressively with PBC stage. Fatigue is strongly associated with impaired HRQL and is closely interrelated with anxiety and depression. Stage-specific psychological patterns suggest the need for tailored supportive interventions.

The gut microbiota engages in a complex, bidirectional dialogue with the liver via the gut–liver axis, and its dysbiosis plays a central role in the initiation and progression of various liver diseases. This review comprehensively integrates recent advances in the common features and etiology-specific patterns of gut microbial dysbiosis in liver diseases, signal decoding of key microbial metabolite axes, gut–liver immune crosstalk mechanisms, the accelerating role of gut barrier disruption, and recent progress in the use of the microbiome as diagnostic and prognostic biomarkers. We focus on analyzing the common patterns of reduced diversity, depletion of beneficial bacteria, and enrichment of pathogenic bacteria associated with gut flora dysbiosis across different liver diseases, ranging from nonalcoholic fatty liver disease and alcoholic liver disease to cirrhosis and hepatocellular carcinoma, as well as their unique etiology-related characteristics. Core findings reveal that microbial metabolites act as key chemical messengers that precisely drive liver disease progression by modulating host metabolic, immune, and inflammatory pathways. Meanwhile, the translocation of microbes and their products resulting from disruption of gut barrier integrity serves as a key accelerator, exacerbating liver injury and related complications. Based on these mechanisms, this review further explores ecological niche remodeling strategies targeting the gut microbiota, including the existing evidence and limitations of fecal microbiota transplantation and probiotics/prebiotics, as well as the prospects of emerging precision interventions such as phage therapy, microbial enzyme inhibitors, and engineered bacteria. Finally, we emphasize the potential and personalized implementation pathways of synergistically integrating microbiota modulation with existing therapies such as antivirals, antifibrotics, immunotherapy, and metabolic surgery. Future research must focus on promoting the translation of microbiome research from association studies to clinical applications through multi-omics integration and prospective clinical trials, ultimately achieving precise prevention and treatment of liver diseases based on gut–liver axis regulation.

Autoimmune pancreatitis (AIP) is a rare immune-mediated form of chronic pancreatitis. It may affect multiple organs, and its heterogeneous clinical manifestations complicate diagnosis and management. Based on the Chinese Guidelines for the Diagnosis and Management of Autoimmune Pancreatitis (Shanghai 2012 Draft), together with the latest domestic and international guidelines and research advances, the present guideline provides 20 recommendations covering four aspects: diagnosis, treatment, follow-up, and prognosis. The aim is to improve the diagnosis and management of AIP in China and ultimately improve patient outcomes.